MacroGenics (NASDAQ:MGNX) Issues Earnings Results, Misses Estimates By $0.02 EPS

MacroGenics (NASDAQ:MGNX) issued its quarterly earnings data on Thursday. The biopharmaceutical company reported ($0.25) EPS for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.02), Zacks reports. The company had revenue of $49.40 million for the quarter, compared to the consensus estimate of $34.17 million. MacroGenics had a negative return on equity of 89.42% and a negative net margin of 69.07%.

MacroGenics Trading Down 9.3 %

MGNX traded down $0.20 during trading on Friday, reaching $1.91. 230,078 shares of the company were exchanged, compared to its average volume of 1,152,235. MacroGenics has a 52 week low of $1.91 and a 52 week high of $19.54. The stock has a market cap of $119.56 million, a P/E ratio of -1.23 and a beta of 2.12. The firm has a 50 day moving average of $2.68 and a 200 day moving average of $3.23.

MacroGenics Company Profile

MacroGenics, Inc, a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens.